Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which radiation therapy is better for liver cancer? new study aims to find out

NCT ID NCT07211815

Knowledge-focused Sponsor: Chifeng Tumor Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of radiation therapy—body gamma knife and VMAT—for people with primary liver cancer who cannot have or refuse surgery. Researchers will look at how well each method targets the tumor and how much it affects nearby organs. The goal is to help patients and doctors choose the best treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with locally advanced primary liver cancer (unsuitable for/refusing surgery, meeting inclusion \& not exclusion criteria), aged 18-75 years, from Chifeng Tumor Hospital.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75 years. * Clinically or pathologically confirmed primary liver cancer; unsuitable for or - refusing surgery, with single tumor diameter ≤5 cm and ≤5 nodules. * ECOG PS score 0-1. * Liver function: Child-Pugh grade A or B. * Prothrombin time (PT) \< 4 seconds above the normal control range. * No hepatic encephalopathy or moderate to large ascites. * Renal and cardiopulmonary function basically normal. * Gastroscopy findings: no severe esophageal varices or active peptic ulcer. * Hemoglobin ≥90 g/L, WBC ≥3.0×10⁹/L, neutrophil ≥1.5×10⁹/L, platelet ≥40×10⁹/L. * No obvious cachexia; life expectancy \> 3 months. * Not pregnant; no HIV or syphilis infection. * Able to understand the study and sign informed consent. Exclusion Criteria: * History of portal hypertension, esophageal variceal bleeding, or related conditions. * History of anti-RHCC treatment or spontaneous tumor rupture. * Postoperative pathology indicates metastatic cancer or other primary cancers. * Cerebrovascular accident within 6 months before enrollment. * Severe lung disease; serum creatinine \> 1.25×the upper normal limit. * Poorly controlled acute or active infection; severe mental illness. * Suspected systemic or local lymphadenopathy on imaging. * Pregnant or lactating women; presence of other serious underlying diseases. * Currently participating in other clinical trials; refusal to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary liver cancers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary liver cancers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chifeng Tumor Hospital

    Chifeng, Inner Mongolia, 024000, China